What 	What 	 WP	O
's  	's  	 VBZ	O
new  	new  	 JJ	O
in  	in  	 IN	O
internal  	internal  	 JJ	B-NP
medicine 	medicine 	 NN	I-NP
:  	:  	 :	O
emerging  	emerging  	 VBG	B-NP
treatments  	treatments  	 NNS	I-NP
for  	for  	 IN	I-NP
systemic  	systemic  	 JJ	I-NP
lupus  	lupus  	 JJ	I-NP
erythematosus  	erythematosus  	 JJ	I-NP
Today  	Today  	 NN	I-NP
corticosteroids  	corticosteroids  	 NNS	I-NP
plus  	plus  	 CC	O
hydroxychloroquine  	hydroxychloroquine  	 NNS	B-NP
are  	are  	 VBP	O
the  	the  	 DT	O
cornerstone  	cornerstone  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
Systemic  	Systemic  	 NNP	B-NP
Lupus  	Lupus  	 NNP	I-NP
Erythematosus  	Erythematosus  	 NNP	I-NP
( 	( 	 -LRB-	O
SLE 	SLE 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
In  	In  	 IN	O
severe  	severe  	 JJ	O
cases 	cases 	 NNS	O
,  	,  	 ,	O
particularly  	particularly  	 RB	O
in  	in  	 IN	O
proliferative  	proliferative  	 JJ	B-NP
glomerulonephritis 	glomerulonephritis 	 NN	I-NP
,  	,  	 ,	O
cyclophosphamide  	cyclophosphamide  	 NN	B-NP
or  	or  	 CC	O
mycofenolate  	mycofenolate  	 JJ	B-NP
mofetil  	mofetil  	 NNS	I-NP
are  	are  	 VBP	O
used  	used  	 VBN	O
in  	in  	 IN	O
induction  	induction  	 NN	B-NP
and  	and  	 CC	O
mycofenolate  	mycofenolate  	 JJ	B-NP
mofetil  	mofetil  	 NN	I-NP
or  	or  	 CC	O
azathioprine  	azathioprine  	 NNS	B-NP
are  	are  	 VBP	O
used  	used  	 VBN	O
to  	to  	 TO	O
maintain  	maintain  	 VB	O
the  	the  	 DT	O
remission 	remission 	 NN	O
.  	.  	 .	O
Corticosteroid  	Corticosteroid  	 JJ	B-NP
sparing  	sparing  	 NN	I-NP
is  	is  	 VBZ	O
an  	an  	 DT	O
important  	important  	 JJ	O
goal 	goal 	 NN	O
.  	.  	 .	O
New  	New  	 NNP	O
and  	and  	 CC	O
future  	future  	 JJ	O
treatments  	treatments  	 NNS	O
of  	of  	 IN	O
SLE  	SLE  	 NNP	B-NP
focus  	focus  	 NN	I-NP
on  	on  	 IN	O
B  	B  	 NNP	O
and  	and  	 CC	O
T  	T  	 NN	B-NP
cells  	cells  	 NNS	I-NP
down  	down  	 IN	O
regulation  	regulation  	 NN	O
and  	and  	 CC	O
co-stimulation 	co-stimulation 	 JJ	B-NP
,  	,  	 ,	O
cytokine  	cytokine  	 JJ	B-NP
inhibition 	inhibition 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
open  	open  	 VB	O
the  	the  	 DT	O
concept  	concept  	 NN	O
of  	of  	 IN	O
immune  	immune  	 JJ	O
vaccination 	vaccination 	 NN	O
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
positive  	positive  	 JJ	B-NP
phase  	phase  	 NN	I-NP
III  	III  	 NNP	I-NP
randomized  	randomized  	 NN	O
studies  	studies  	 NNS	O
in  	in  	 IN	O
SLE  	SLE  	 NNP	B-NP
remain  	remain  	 VBP	O
rare 	rare 	 JJ	O
.  	.  	 .	O
Rituximab  	Rituximab  	 NNP	B-NP
( 	( 	 -LRB-	O
a  	a  	 DT	O
chimeric  	chimeric  	 JJ	B-NP
monoclonal  	monoclonal  	 JJ	I-NP
anti-CD  	anti-CD  	 JJ	I-NP
20  	20  	 CD	O
antibody 	antibody 	 NN	B-NP
)  	)  	 -RRB-	O
was  	was  	 VBD	O
the  	the  	 DT	O
first  	first  	 JJ	O
promising  	promising  	 JJ	O
biologic  	biologic  	 JJ	B-NP
agent  	agent  	 NN	I-NP
showing  	showing  	 VBG	O
interesting  	interesting  	 JJ	O
results  	results  	 NNS	O
in  	in  	 IN	O
large  	large  	 JJ	O
case  	case  	 NN	B-NP
series  	series  	 NN	I-NP
but  	but  	 CC	O
2  	2  	 CD	O
phases  	phases  	 NNS	O
III  	III  	 NNP	O
randomised  	randomised  	 NN	O
studies  	studies  	 NNS	O
did 	did 	 VBD	O
n't  	n't  	 RB	O
reach  	reach  	 VB	O
their  	their  	 PRP$	O
primary  	primary  	 JJ	B-NP
objective 	objective 	 NN	I-NP
.  	.  	 .	O
This  	This  	 DT	O
probably  	probably  	 RB	O
emphasizes  	emphasizes  	 VBZ	O
the  	the  	 DT	O
limit  	limit  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
current  	current  	 JJ	O
tools  	tools  	 NNS	O
used  	used  	 VBN	O
for  	for  	 IN	O
the  	the  	 DT	O
evaluation  	evaluation  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
disease  	disease  	 NN	O
and  	and  	 CC	O
point  	point  	 NN	O
out  	out  	 IN	O
the  	the  	 DT	O
design  	design  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
studies  	studies  	 NNS	O
using  	using  	 VBG	O
high  	high  	 JJ	O
dose  	dose  	 NN	O
of  	of  	 IN	O
corticosteroids 	corticosteroids 	 NN	B-NP
,  	,  	 ,	O
immunosuppressive  	immunosuppressive  	 JJ	B-NP
drugs  	drugs  	 NNS	I-NP
and  	and  	 CC	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
rituximab  	rituximab  	 VBG	O
as  	as  	 RB	O
add  	add  	 VB	O
on  	on  	 IN	O
treatment  	treatment  	 NN	O
and  	and  	 CC	O
are  	are  	 VBP	O
not  	not  	 RB	O
face  	face  	 VB	O
to  	to  	 TO	O
face  	face  	 VB	O
with  	with  	 IN	O
conventional  	conventional  	 JJ	B-NP
treatment 	treatment 	 NN	I-NP
.  	.  	 .	O
Abatacept  	Abatacept  	 NNP	B-NP
( 	( 	 -LRB-	O
CTLA4-Ig 	CTLA4-Ig 	 NNP	B-NP
)  	)  	 -RRB-	O
also  	also  	 RB	O
failed  	failed  	 VBN	O
to  	to  	 TO	O
meet  	meet  	 VB	O
its  	its  	 PRP$	O
primary  	primary  	 JJ	B-NP
end  	end  	 NN	I-NP
point  	point  	 NN	I-NP
in  	in  	 IN	O
a  	a  	 DT	O
randomised  	randomised  	 JJ	B-NP
controlled  	controlled  	 JJ	I-NP
trial  	trial  	 NN	I-NP
in  	in  	 IN	O
non-nephritis  	non-nephritis  	 NNP	B-NP
SLE 	SLE 	 NNP	I-NP
.  	.  	 .	O
A  	A  	 DT	O
post-hoc  	post-hoc  	 JJ	B-NP
analysis  	analysis  	 NN	I-NP
suggests  	suggests  	 VBZ	O
however  	however  	 RB	O
that  	that  	 IN	O
abatacept  	abatacept  	 NNS	B-NP
may  	may  	 MD	O
be  	be  	 VB	O
beneficial  	beneficial  	 JJ	O
in  	in  	 IN	O
lupus  	lupus  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
with  	with  	 IN	O
arthritis  	arthritis  	 NN	O
however 	however 	 RB	O
,  	,  	 ,	O
it  	it  	 PRP	O
will  	will  	 MD	O
probably  	probably  	 RB	O
never  	never  	 RB	O
be  	be  	 VB	O
approved  	approved  	 VBN	O
for  	for  	 IN	O
that  	that  	 DT	O
indication 	indication 	 NN	O
.  	.  	 .	O
Belimumab  	Belimumab  	 NNP	B-NP
( 	( 	 -LRB-	O
a  	a  	 DT	O
human  	human  	 JJ	O
monoclonal  	monoclonal  	 JJ	B-NP
antibody  	antibody  	 NN	I-NP
to  	to  	 TO	O
BLyS 	BLyS 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
the  	the  	 DT	O
first  	first  	 JJ	O
biologic  	biologic  	 JJ	B-NP
agent  	agent  	 NN	I-NP
which  	which  	 WDT	O
reached  	reached  	 VBD	O
its  	its  	 PRP$	O
primary  	primary  	 JJ	B-NP
end  	end  	 NN	I-NP
point  	point  	 NN	I-NP
in  	in  	 IN	O
2  	2  	 CD	O
different  	different  	 JJ	O
randomised  	randomised  	 NNS	O
controlled  	controlled  	 VBN	B-NP
trials  	trials  	 NNS	I-NP
using  	using  	 VBG	O
a  	a  	 DT	O
new  	new  	 JJ	O
index  	index  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
evaluation  	evaluation  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
activity  	activity  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
diseases  	diseases  	 NNS	O
taking  	taking  	 VBG	O
into  	into  	 IN	O
account  	account  	 NN	O
the  	the  	 DT	O
physicians  	physicians  	 JJ	B-NP
judgement  	judgement  	 NNS	I-NP
( 	( 	 -LRB-	O
SLE  	SLE  	 NNP	B-NP
responder  	responder  	 JJ	I-NP
index 	index 	 NN	I-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Lots  	Lots  	 NNS	O
of  	of  	 IN	O
phase  	phase  	 NN	B-NP
I 	I 	 PRP	I-NP
/ 	/ 	 VBZ	I-NP
II  	II  	 NNP	I-NP
studies  	studies  	 NNS	I-NP
are  	are  	 VBP	O
currently  	currently  	 RB	O
ongoing  	ongoing  	 JJ	O
particular  	particular  	 JJ	O
targeting  	targeting  	 NN	O
on  	on  	 IN	O
interferon  	interferon  	 JJ	O
alpha 	alpha 	 NN	O
,  	,  	 ,	O
interleukin  	interleukin  	 CD	B-NP
6 	6 	 CD	O
,  	,  	 ,	O
B  	B  	 NNP	B-NP
cell  	cell  	 NN	I-NP
CD22  	CD22  	 NN	I-NP
and  	and  	 CC	O
C5  	C5  	 CD	B-NP
complement  	complement  	 JJ	I-NP
component 	component 	 NN	I-NP
.  	.  	 .	O
